AZUNOU UTUMU JIMS 31 USBAR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Deborah Addison et al.

For

: MEDICATED POLYURETHANE FOAMS

Commissioner for Patents P.O. Box 1450 / Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth

in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. П In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with | the first or second After Final Submission, therefore: П Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10the fee of \$180.00 as set forth / in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: П Statement in Accordance with §1.97(e) (attached); or П Please charge Deposit Account No. 10-/ the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

C	opies of each of the references listed on the						
attached Form PTO-1449 are enclosed herewith.							
□ c	opies of references listed on the attached Form PTO-						
1449 are end	closed herewith EXCEPT THAT:						
	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.						
	If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.						
	opies of only foreign patent documents and non- rature are enclosed in accordance with 37 CFR 1.98						
⊠ T English land	here are no listed references which are not in the guage.						
The relevance of those listed references which are not in the English language is as follows:							
Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.							
A	ttached are the following non-published pending						
	ications which may be deemed relevant, which are						
listed on t	he attached Submission Under MPEP 609 D.						

Please charge any deficiency or credit any overpayment to Deposit Account No. $10-0750/\mathrm{JJM5021USPCT/BEL}$. This form is submitted in triplicate.

Respectfully submitted,

/Blossom E. Loo/

Blossom E. Loo Reg. No. 36,858 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1596 DATED: July 31, 2006

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

a collection or information onless it displays a	VALU OND CONTO HUMBER.		
Application Number	102/995		
Filing Date	, , , 0, , , ,		
First Named Inventor	Deborah Addison		
Group Art Unit			
Examiner Name			
Attorney Docket Number	JJM5031USPCT		

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite	U.S. Patent Document Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		4339550	Α	Palinczar et al.	07-13-1982	
· • · · · · · · · · · · · · · · · · · ·		5776495	Α	Duclos et al.	07-07-1998	
		5833665	Α	Bootman et al.	11-10-1998	
		2002/168400	A1	Jain	11/14/2002	
						-
	<u> </u>					

Examiner Initials	Cite	Foreign Patent Document Office ³ Number ⁴ KindCode ⁵			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		EP	1112739	Α	Sumitomo Pharm. Co. Ltd	07-04-2001		x
		wo	00/47241	Α	Johnson & Johnson Medical	08-17-2000		X
		wo	02/45761	Α	Johnson & Johnson Medical	06-13-2002		X
-								

Examiner	Date
Signature	Considered
Chipicialic	

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.